Regeneron Pharmaceuticals Inc (REGN)

Operating profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	4,047,100	4,221,000	4,333,700	4,427,100	4,738,900	6,231,800	6,855,300	9,092,600	8,946,800	7,474,100	6,680,000	3,989,200	3,576,600	3,085,300	2,770,700	2,429,900	2,209,800	2,252,200	2,140,600	2,447,200
Revenue (ttm)	US$ in thousands	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900	7,839,900	7,598,200	7,213,600	6,889,000
Operating profit margin		31.03%	32.41%	34.39%	35.97%	39.12%	45.64%	48.37%	55.27%	55.87%	55.36%	54.18%	43.61%	42.30%	37.62%	34.74%	30.53%	28.19%	29.64%	29.67%	35.52%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $4,047,100K ÷ $13,044,200K
= 31.03%

Regeneron Pharmaceuticals, Inc.'s operating profit margin has shown a declining trend over the past eight quarters, indicating potential challenges in managing operating expenses relative to revenue generation. The company's operating profit margin decreased from 55.10% in Q1 2022 to 32.26% in Q4 2023. This downward trajectory suggests a decrease in the efficiency of converting revenue into profits, which could be attributed to factors such as rising costs or pricing pressures in the pharmaceutical industry. It is important for the company to closely monitor and address the underlying factors driving this decline to ensure sustainable profitability and operational efficiency in the future.